Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. - Tu, Ya‐Ping; Lagraauw, H. Maxime; Method, Michael; Wang, Yuemei; Hanze, Eva; Li, Lingling; Parrott, Timothy; Sloss, Callum M.; Westin, Eric H. (British Journal of Clinical Pharmacology, 2025)